NOVEL BETS: PART 2- Mapping India's #PHARMA #INNOVATION
Abhishek Basumallick • 3 days ago
What This Video Is About
This video is the second part of a pharma industry session, focusing on Sun Pharma's novel bet, Lexelvi. The company acquired Lexelvi as part of a larger acquisition in 2023 and has been able to launch the drug despite a patent war.
Major Ideas Discussed
- Sun Pharma has a proven track record of identifying, acquiring, and commercializing assets at scale, which has laid the foundation for its innovation model.
- Lexelvi is a drug used to treat alopecia areata, an autoimmune condition, and has the potential to become a blockbuster drug.
- The company faced a patent war with Insight but was able to launch Lexelvi in July 2025 after an undisclosed settlement.
- Sun Pharma is exploring the potential of Lexelvi in treating other autoimmune diseases.
- The company's innovative medicines segment, renamed "Innovative Medicines" in September 2025, contributes 22% to overall sales.
What to Watch Next
The progress of Lexelvi and Sun Pharma's innovative medicines segment will be monitored for future updates, including potential expansions into other autoimmune diseases.